Page last updated: 2024-11-04

sevoflurane and Cockayne Syndrome

sevoflurane has been researched along with Cockayne Syndrome in 1 studies

Sevoflurane: A non-explosive inhalation anesthetic used in the induction and maintenance of general anesthesia. It does not cause respiratory irritation and may also prevent PLATELET AGGREGATION.
sevoflurane : An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups.

Cockayne Syndrome: A syndrome characterized by multiple system abnormalities including DWARFISM; PHOTOSENSITIVITY DISORDERS; PREMATURE AGING; and HEARING LOSS. It is caused by mutations of a number of autosomal recessive genes encoding proteins that involve transcriptional-coupled DNA REPAIR processes. Cockayne syndrome is classified by the severity and age of onset. Type I (classical; CSA) is early childhood onset in the second year of life; type II (congenital; CSB) is early onset at birth with severe symptoms; type III (xeroderma pigmentosum; XP) is late childhood onset with mild symptoms.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Raghavendran, S1
Brown, KA1
Buu, N1

Other Studies

1 other study available for sevoflurane and Cockayne Syndrome

ArticleYear
Perioperative management of patients with Cockayne syndrome - recognition of accelerated aging with growth arrest.
    Paediatric anaesthesia, 2008, Volume: 18, Issue:4

    Topics: Adjuvants, Anesthesia; Adolescent; Aging; Anesthesia; Anesthetics, Inhalation; Cockayne Syndrome; Fe

2008